Original Article

You have free access to this content

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma†

Results of a large phase 2 study

  1. David J. Vaughn MD1,‡,*,
  2. Sandy Srinivas MD2,
  3. Walter M. Stadler MD3,
  4. Roberto Pili MD4,
  5. Daniel Petrylak MD5,
  6. Cora N. Sternberg MD6,
  7. David C. Smith MD7,
  8. Sarah Ringuette MD8,
  9. Edwin de Wit MD8,
  10. Virginie Pautret MD9,
  11. Claude George MD10

Article first published online: 17 JUN 2009

DOI: 10.1002/cncr.24460

Issue

Cancer

Cancer

Volume 115, Issue 18, pages 4110–4117, 15 September 2009

Additional Information

How to Cite

Vaughn, D. J., Srinivas, S., Stadler, W. M., Pili, R., Petrylak, D., Sternberg, C. N., Smith, D. C., Ringuette, S., de Wit, E., Pautret, V. and George, C. (2009), Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma. Cancer, 115: 4110–4117. doi: 10.1002/cncr.24460

Author Information

  1. 1

    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

  2. 2

    Department of Medicine, Stanford University, Stanford, California

  3. 3

    Department of Medicine, University of Chicago, Chicago, Illinois

  4. 4

    Department of Medicine, Johns Hopkins University, Baltimore, Maryland

  5. 5

    Department of Medicine, Columbia University, New York, New York

  6. 6

    Department of Medicine, San Camillo Forlanini Hospital, Rome, Italy

  7. 7

    Department of Medicine, University of Michigan, Ann Arbor, Michigan

  8. 8

    Bristol-Myers Squibb, Wallingford, Connecticut

  9. 9

    Bristol-Myers Squibb, Braine L'Alleud, Belgium

  10. 10

    Bristol-Myers Squibb, Princeton, New Jersey

  1. ‡

    Fax: (215) 662-7804

*Abramson Cancer Center of the University of Pennsylvania, 16 Penn Tower, 300 Spruce Street, Philadelphia, PA 19104

  1. †

    Presented in part at the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007; and the American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, California, February 14-16, 2008.

Publication History

  1. Issue published online: 4 SEP 2009
  2. Article first published online: 17 JUN 2009
  3. Manuscript Accepted: 26 JAN 2009
  4. Manuscript Revised: 16 JAN 2009
  5. Manuscript Received: 25 NOV 2008

Funded by

  • Bristol-Myers Squibb

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (162K)

References

  • 1
    Loehrer PJSr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, cisplatin, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10: 1066-1073.
  • 2
    von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 3068-3077.
  • 3
    von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602-4608.
  • 4
    Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007; 69: 62-79.
  • 5
    Garcia JA, Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol. 2006; 24: 5545-5551.
  • 6
    Iaffailoi RV, Milano A, Caponigro F. Therapy of metastatic bladder carcinoma. Ann Oncol. 2007; 18( supp 6): vi153-vi156.
  • 7
    Fahy J, Duflos A, Ribet JP, et al. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc. 1997; 119: 8576-8577.
  • 8
    Fahy J. Modifications in the “upper” velbanamine part of the Vinca alkaloids have major implications for tubulin interacting activities. Curr Pharm Des. 2001; 7: 1181-1197.
  • 9
    Hill BT, Fiebig HH, Waud WR, et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer. 1999; 35: 512-520.
  • 10
    Kruczynski A, Colpaert F, Tarayre JP, et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol. 1998; 41: 437-447.
  • 11
    Bonfil RD, Russo DM, Binda MM, et al. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol. 2002; 7: 159-166.
  • 12
    Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006; 94: 1395-1401.
  • 13
    Bellmunt Molins J, von der Maase H, Theodore C, et al. Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU) [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 5028.
  • 14
    World Health Organization. WHO Handbook for Reporting of Cancer Treatment. World Health Organization Offset Pub. No. 48. Geneva, Switzerland: World Health Organziation; 1979.
  • 15
    Bennouna J, Campone M, Delord JP, et al. Vinflunine: a novel antitubulin agent in solid malignancies. Expert Opin Investig Drugs. 2005; 14: 1259-1267.
View Full Article (HTML) Get PDF (162K)